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Background: Glioma stem cells in the quiescent state are resistant to clinical radiation therapy. An almost
inevitable glioma recurrence is due to the persistence of these cells. The high linear energy transfer associated with
boron neutron capture therapy (BNCT) could kill quiescent and proliferative cells.
Methods: The present study aimed to evaluate the effects of BNCT on glioma stem/progenitor cells in vitro. The
damage induced by BNCT was assessed using cell cycle progression, apoptotic cell ratio and apoptosis-associated
proteins expression.
Results: The surviving fraction and cell viability of glioma stem/progenitor cells were decreased compared with
differentiated glioma cells using the same boronophenylalanine pretreatment and the same dose of neutron flux.
BNCT induced cell cycle arrest in the G2/M phase and cell apoptosis via the mitochondrial pathway, with changes
in the expression of associated proteins.
Conclusions: Glioma stem/progenitor cells, which are resistant to current clinical radiotherapy, could be effectively
killed by BNCT in vitro via cell cycle arrest and apoptosis using a prolonged neutron irradiation, although
radiosensitivity of glioma stem/progenitor cells was decreased compared with differentiated glioma cells when
using the same dose of thermal neutron exposure and boronophenylalanine pretreatment. Thus, BNCT could offer
an appreciable therapeutic advantage to prevent tumor recurrence, and may become a promising treatment in
recurrent glioma.
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Human glioblastoma multiforme (GBM) is the most ag-
gressive type of brain tumors and has a poor prognosis.
Although current therapies (based on surgical resection,
radiotherapy and chemotherapy) modestly improve pa-
tient survival, about 75% of patients will die within
2 years of diagnosis [1]. There is currently no cure for
GBM, because the surgeon cannot completely remove
this diffuse tumor. Radiotherapy remains the key com-
ponent of GBM treatment, and most attempts to in-
crease its intensity were hampered by unacceptable late
toxicities [2]. There are increasing evidences that GBM* Correspondence: Zhouyxyq2008@sohu.com
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reproduction in any medium, provided the orpossess small numbers of ‘stem-like’ cells, called glioma
stem cells (GSC), which are able to give rise to a new
tumor closely similar to the original cancer. The almost
inevitable GBM recurrence is due to the persistence of
these cells despite multimodality treatment [3,4]. It has
been proposed that these tumor-initiating cells are re-
sistant to radiation therapy, and that this property con-
tributes to the poor treatment outcomes associated with
these tumors [5,6]. Since escalating treatment intensity
is associated with unacceptable damage to normal brain,
alternative methods of overcoming this resistance are ur-
gently required.
Boron neutron capture therapy (BNCT) theoretically
provides a way to selectively destroy boron-10 (10B)-
loaded malignant cells, sparing normal cells without 10B.
As stated by Barth and his co-authors [7], BNCT is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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occur when 10B, a nonradioactive boron isotope, is irra-
diated using low-energy thermal neutrons. This fission
reaction produce high linear energy transfer (LET) α
particles (4He) and lithium-7 (7Li) nuclei.
For BNCT to be successful, the tumor must contain
high levels of 10B (~20 μg/g or ~109 atoms/cell), while
peripheral normal tissue must contain only small levels.
In addition, a sufficient amount of thermal neutrons
must be delivered to the tumor tissue to sustain a lethal
10B(n,a)7Li reaction [8,9]. The destructive effects of these
high-energy particles, which only have a limited penetra-
tion power in tissue (5–9 μm), are thus limited to
boron-containing cells [7-9]. The high LET radiation as-
sociated with BNCT would kill anoxic and quiescent
cells, as well as oxygenated and proliferative cells [10].
In theory, GSC would be killed by neutrons as long as a
sufficient dose of 10B is absorbed by the GCS.
Radiosensitivity of tumor cells is associated with cell
differentiation [11]. The characteristics of glioma stem/
progenitor cells (GSPC) SU2, which were used in this re-
search, were between glioma stem cells and progenitor
cells. The SU2 cells are radioresistant to certain doses of
X-rays [12]. To the best of our knowledge, there is a lack
of relevant data on the effects of BNCT on GSPC. The
purpose of the present study was to assess the in vitro
effects of BNCT on GSPC and differentiated glioma
cells, using the In-Hospital Neutron Irradiator (IHNI-1),
which is a low-power research reactor using a miniature
neutron source [13].Table 1 Total neutron radiation doses according to
exposure time






SU2 2 min 0.412 0.033 0.445
4 min 0.824 0.066 0.890
6 min 1.235 0.100 1.335
8 min 1.647 0.133 1.780
10 min 2.059 0.166 2.225
SHG-44 2 min 0.585 0.033 0.618
4 min 1.170 0.066 1.236
6 min 1.755 0.100 1.854
8 min 2.340 0.133 2.472
10 min 2.925 0.166 3.090Materials and methods
Cell lines
The SU2 cell line, generously provided by Professor
Qiang Huang, is a GSPC line [14,15]. The SU2 cells
were cultured in serum-free DMEM/F12 medium (1:1)
(Sigma-Aldrich, Tokyo, Japan) containing human re-
combinant N2, EGF and bFGF (20 ng/ml; Invitrogen,
Carlsbad, CA, USA). The SHG-44 cell line is a differenti-
ated human glioma cell line [16]. The SHG-44 cells were
cultured in PRI-1640 supplemented with 10% of fetal bo-
vine serum. Both cell lines were maintained at 37°C in a
5% CO2 atmosphere, and were used to study the effects of
BNCT.
The cells were collected with trypsin/EDTA during the
logarithmic phase, and were seeded in dishes containing
nutrient medium. The cells were incubated for 24 h with
5 mM of boronophenylalanine (BPA) (Boron Biologicals
Inc., Raleigh, NC, USA)-fructose (Sigma Chemical Co.)
complex (50 mg/L of 10B equivalent). Medium con-
taining boron was discarded just before the cells were
irradiated. BPA-free cells were used as control. The con-
centration of 10B was 1.76 ± 0.28 μg/107 cells in the SU2cells and 2.50 ± 0.12 μg/107 cells in the SHG-44 cells at
the moment of neutron irradiation [17].
Neutron irradiation
The irradiation experiments were performed at the
IHNI-1, using a reactor at the full power of 30 KW with
a thermal neutron flux of 1 × 109n/(cm2 · s). The compo-
nents of the reactor neutron source and the irradiation
doses calculated according to a previous study [18] are
shown in Table 1.
Clonogenic surviving assay
Cells were seeded in 6-well plates at a density of
200–1000 cells per well after irradiation. Cells were
subsequently cultured for 3 weeks and medium was
changed every three days. Colonies were stained with
0.1% crystal violet and colonies of more than 50 cells
were counted. The percent plating efficiency and sur-
viving fraction were calculated based on the survival
of non-irradiated cells.
Cell proliferation assay
All cells were seeded in 96-well plates at a density of
1000 cells per well after a 4-minute irradiation. After 1,
2 or 3 days of incubation, proliferation of SU2 and SHG-
44 cells was assessed using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay (Sigma,
St Louis, MO, USA). Optical density was recorded using a
microplate reader at 495 nm. Cellular proliferation was
expressed as a percentage, compared with non-irradiated
cells being 100%.
Cell cycle analysis
Cells were harvested 24 h after a 4-minute irradiation,
washed with phosphate buffered solution (PBS), and fixed



















Figure 1 Surviving curves of SHG-44 and SU2 cells incubated
with or without BPA and exposed to 0, 2, 4, 6, 8 and 10 min
neutron radiations, determined by clonogenic assay. *P < 0.05,
**P < 0.01 SHG-44 cells after BNCT (◇) vs. neutron radiations alone in
SHG-44 cells (◆) for the same time point; # P < 0.05, ##P < 0.01 SU2
cells after BNCT (□) vs. neutron radiations alone in SU2 cells (■) for
the same time point; $P < 0.05, $$P < 0.01 SU2 cells after BNCT vs.
SHG-44 cells after BNCT for the same time point.
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37°C, and incubated in 10 μg propidium iodide (PI)
solution. Cell cycle distribution was determined using
a FACScan flow cytometer (Beckman Coulter, Brea,
CA, USA).
Cell apoptosis assay
After BNCT, cells were washed twice in cold PBS and
resuspended in cold binding buffer. After incubation
with Annexin V-FITC and PI for 15 min, cells were ana-
lyzed by a FACScan flow cytometer. The Annexin V
FITC-positive cells were early apoptotic cells. Data were
expressed as the percentage of Annexin V-FITC-positive
cells in the total number of cells counted.
Western blot
Cell lysates were prepared in RIPA lysis buffer (Cell Sig-
naling Technology, Danvers, MA, USA). Cell debris
were removed by centrifugation at 10,000 g for 10 min
at 4°C. The protein concentration was determined using
the Bradford dye binding assay (Bio-Rad Laboratories,
Hercules, CA, USA). Total proteins were fractionated
by sodium dodecylsulfonate polyacrylamide gel elec-
trophoresis (SDS-PAGE) at 100 V for 80 min at room
temperature, and transferred onto PVDF membrane
(Perkin Elmer, Waltham, MA, USA). Target proteins
were detected using rabbit monoclonal anti-cyclin-B1,
CDK1, cytochrome c and caspase-9 antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit
polyclonal anti-β-actin antibody (Sigma, St Louis, MO,
USA). Immune complexes were detected with horse-
radish peroxidase (HRP)-conjugated anti-rabbit IgG
goat antibodies (Amersham Biosciences, Little Chalfont,
UK). The blots were visualized by chemiluminescence
(Invitrogen, Carlsbad, CA, USA), and densitometric quan-
tification was analyzed using the Launch Sensi Ansys
software.
Statistical analyses
Each experiment was repeated at least three times. Nu-
merical data are presented as the mean ± standard devia-
tions (SD). Data were analyzed using two-tailed t-test or
one-way ANOVA. All statistical analyses were performed
using SPSS 10.0 (SPSS Inc., Chicago, IL, USA).
Results
Suppression of cell survival by BNCT
After exposure to neutron radiations, the surviving frac-
tions of SU2 and SHG-44 cells were examined using a
clonogenic assay. Cell surviving curves were obtained
after neutron irradiation according to the linear quad-
ratic model (Figure 1). In both cell lines, surviving ratios
were decreased in a dose-dependent manner, but SHG-
44 cells were suppressed more strongly than SU2 cells.The surviving fractions of both cells lines pretreated
with BPA at the same amount of radiations were signifi-
cantly decreased compared with BPA-free cells (P < 0.05
for SU2 cells when irradiated for 4 min, and P < 0.05 for
SHG-44 cells when irradiated for 2 min). These results
suggest that the survival of SU2 was higher compared
with SHG-44 cells using the same BPA pretreatment
dose and neutron treatment (P < 0.05 for 2, 4, 6 min,
and P < 0.01 for 10 min).
Suppression of cell proliferation by BNCT
We examined the effects of BNCT on the proliferation
of SU2 and SHG-44 cells in vitro using a MTT assay.
Cell viability after a 4-minute neutron irradiation was
assessed daily for 3 days (Figure 2). Treatment with BPA
before BCNT inhibited proliferation of the two cell lines
in a time-dependent manner. A 32% inhibition of SU2
growth (P < 0.01) and 88% in SHG-44 (P < 0.01) were ob-
served 72 h after BNCT. SU2 cells viability was signifi-
cantly decreased 48 h (P < 0.05) after BNCT, and this
decrease occurred at 24 h in SHG-44 cells (P < 0.05).
These results suggest that the proliferation of SU2 GSPC
was decreased after BNCT.
Induction of cell cycle arrest by BNCT
Cell cycle arrest in SU2 and SHG-44 cells was investiga-
ted by flow cytometry after neutron irradiation (Figure 3).
After BNCT, there was no increase of G0/G1 phase cells.
The proportion of SHG-44 cells in the G2/M phase was
increased from 9.12 ± 0.52% to 20.13 ± 2.85% (P < 0.01).






























Figure 2 BNCT inhibited the proliferation of SHG-44 and SU2
cells at 24, 48 and 72 h after a 4-minute neutron irradiation.
The cell viability after neutron radiations alone was used as a
control. *P < 0.05, **P < 0.01 compared with neutron radiations alone
in SHG-44 cells; #P < 0.05, ##P < 0.01 compared with neutron
radiations alone in SU2 cells; $P < 0.05, $$P < 0.01 compared with
BNCT in SHG-44 cells.
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In SU2 cells, the G2/M population was significantly in-
creased from 8.09 ± 1.67% to 14.60 ± 1.64% (P < 0.01)
after BNCT, and the S population was decreased from
26.10 ± 1.24% to 22.57 ± 3.42%. These results indicate
that cell cycle was arrested at the G2/M checkpoint after
BNCT, and that this arrest was more important in SHG-
44 cells (P < 0.05).
Induction of apoptosis by BNCT
After neutron irradiation, apoptosis of SHG-44 and SU2
cells was quantitatively measured using flow cytometry.
As shown in Figure 4, the average apoptotic rate of SHG-
44 cells was higher after BNCT (75.2 ± 4.81%) compa-























Figure 3 Cell cycle distribution of SHG-44 and SU2 cells after a
4-minute neutron irradiation. *P < 0.05, **P < 0.01 compared with
neutron radiations alone in SHG-44 cells; ##P < 0.01 compared with
neutron radiations alone in SU2 cells; $P < 0.05 compared with BNCT
in SHG-44 cells.while the apoptotic proportion in SU2 cells after BNCT
was only 11.5 ± 0.87%. These results suggest that the
apoptotic ratio of SHG-44 cells was higher compared with
SU2 cells (P < 0.01) after BNCT using the same dose of
BPA and neutron radiations.
Effects of BNCT on cyclin B1, CDK1, caspase-9 expression
and release of cytochrome c
As G2/M phase-associated proteins, cyclin B1 and
CDK1 were determined in SHG-44 and SU2 cells after
neutron irradiation. As shown in Figure 5, a more obvi-
ous decrease in cyclin B1 and CDK1 levels were ob-
served in SHG-44 cells compared with SU2 cells after
BNCT. Cytochrome c levels in cytosol, a marker of
apoptosis, were increased in SHG-44 and SU2 cells
treated with BNCT, and more obvious increases were
observed in SHG-44 compared with SU2 cells. Consist-
ently, cleavage of caspase-9, an additional marker of
apoptosis, was also increased in both cell lines following
BNCT. The relative levels of target proteins expression
were normalized against protein levels of β-actin assessed
in the same experiments.
Discussion
The present study confirmed that GSPC could be killed
by BNCT, although higher radiation doses were needed
compared with differentiated glioma cells. A previous
study showed that CD133+ cells were more resistant to
ionizing radiations than the corresponding CD133− cells
[19]. SU2 GSPC, compared with differentiated glioma
SHG-44 cells, has been confirmed to be radioresistant to
conventional X-rays radiotherapy, while survival was de-
creased in SHG-44 cells with increasing doses of X-rays
[12]. The same trend was observed in SU2 cells, but
their survival was significantly higher than SHG-44 cells
using identical X-ray doses, and the ratio of CD133+
cells was increased 3.0-3.6 times compared with before
irradiation [12]. Utsumi et al. confirmed that X-ray-sen-
sitive P-39 and X-ray-resistant G-361 human melanoma
cell lines had similar sensitivity to thermal neutron ir-
radiation after pretreatment with BPA [20]. To date,
many studies performed on different cell types showed
that cellular viability was decreased after BNCT [20-23].
However, most of the studies on BNCT focused on dif-
ferentiated cancer cells, and there is no doubt that these
cells could be effectively damaged in vitro and in vivo. In
this present study, we used a GSPC line (SU2) and a dif-
ferentiated glioma cell line (SHG-44) to investigate the
effects of BNCT on different sub-population of tumor
cells. Our previous study demonstrated that the concen-
tration of 10B in GSPC SU2 cultured in 5 mM BPA
could meet the concentration required for BNCT, al-
though this concentration was lower than in SHG-44
cells [17]. Differences in 10B uptake between SHG-44
Figure 4 Proportion of apoptotic SHG-44 and SU2 cells after a 4-minute neutron irradiation. Apoptotic rate of BNCT in SHG-44 cells
(C) was significantly increased compared with neutron radiations alone in SHG-44 cells (A), neutron radiations alone in SU2 cells (B) and BNCT in
SU2 cells (D).
Figure 5 Protein expression associated with cell cycle and
apoptosis. After a 4-minute irradiation, protein expression was
changed in neutron radiations alone in SHG-44 cells (A), neutron
radiations alone in SU2 cells (B), BNCT in SHG-44 cells (C) and BNCT
in SU2 cells (D).
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tabolism of GSPC compared with differentiated tumor
cells. Thus, the total radiation doses were different be-
tween SU2 and SHG-44 cells using the same neutron
flux. The in vitro effects of BNCT were evaluated com-
paratively according to 10B-content in the cells and the
subsequent dosimetry to predict the cell surviving prob-
ability [24]. After BNCT, viability was significantly de-
creased in SU2 cells compared with SHG-44 cells using
the same neutron flux, which demonstrated that GSPC
were more resistant to BNCT than differentiated glioma
cell. Beside the 10B(n,α)7Li reaction, other effects (in-
cluding reactions of hydrogen and nitrogen, and γ-rays)
are produced by the IHNI-1, decreasing the surviving
fraction and viability of BPA-free cells after irradiation
by the IHNI-1.
BNCT has also been shown to interfere with cell cycle
progression as a function of BPA concentration and
thermal neutron dose. High LET radiations, such as α
particles, induce more extensive delays in the S or G2
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the different radiobiological effects of high LET particle
beams with respect to impacts on cell cycle control [26].
Our results showed that cell cycle was arrested at the
G2/M checkpoint in SHG-44 and SU2 cells after BNCT.
Cyclin B1 accumulates and forms a kinase complex with
CDK1 during the G2 phase, and G2/M arrest has been
associated with an inhibition or a delay in the activation
of CDK1 in association with their specific regulatory
cyclin B1 proteins [27,28]. Thus, we analyzed the levels
of cyclin B1 and CDK1 expression, and the results
showed a decreased expression of cyclin B1 and CDK1
proteins after BNCT. Faiao-Flores et al. [21] also showed
that BNCT treatment reduced the cells in G0/G1 and
G2/M phases, which was proven by the reduction of
cyclin D1, and increased amounts of fragmented DNA
in melanoma cells. Perona et al. [22] showed that cell
cycle was arrested in G2/M 24 and 48 h after BNCT,
and that cell death was mostly produced by cell necrosis.
The p53 protein was up-regulated 24 h after BNCT,
which did not seem to be correlated with the p53-
dependent G1/S cell cycle arrest. These previous studies
concur with our conclusion on G2/M phase arrest in-
duced by BNCT. Meanwhile, cells in the G2/M phase
are the most sensitive to ionizing radiations. Exposure of
cells to X- or γ-rays results in a division delay including
G1 arrest, G2 arrest or S phase delay. The G2 arrest is
seen in virtually all eukaryotic cells following high- or
low-dose irradiation, which is one mechanism of cell
damage in conventional radiotherapy [29]. One possible
mechanism underlying an intrinsic radioresistant GSC
was the higher activation of early DNA damage cell cycle
checkpoint proteins [19].
Apoptosis induced by radiation is a degradative and
progressive process. The degradative process is initiated
in the target nucleus, ultimately resulting in the quanti-
tative conversion of the target genome into small DNA
fragments [29]. An increased apoptosis was demonstra-
ted by flow cytometry in BNCT-treated cells compared
with non-irradiated cells. Wang et al. confirmed that
BNCT-induced apoptosis was mediated by the Bcl-2/
Bax pathway in glioma cells [23]. In the present study,
Western blot revealed changes in cytochrome c and
caspase-9 proteins associated with BNCT-induced apop-
tosis. The induction of cytochrome c release into cytosol
by neutron irradiation suggested that BNCT might in-
duce apoptosis by the mitochondria-mediated pathway.
Increased cytochrome c interacts with Apaf-1, forming a
complex to activate caspase-9. The activated caspase-9 is
cleaved and thereby induces the activation of other cas-
pases, such as caspase-3, which subsequently contribute
to apoptotic cell death. Another study [21] evaluated the
mechanisms of neutron irradiation and showed that
BNCT induced a decrease in mitochondrial potential,causing cell death in B16F10 murine melanoma. DNA
fragmentation in B16F10 melanoma was extremely sig-
nificant, but death of these cells did not occur by means
of intrinsic apoptosis, because the increase of phosphor-
ylated caspase-3 did not take place. During conventio-
nal X-ray radiotherapy, exposure to ionizing radiations
elicits a preferential activation of the DNA damage re-
sponse pathway, while release of cytochrome c into cyto-
sol and activation of caspase-9 occur after exposure to
ionizing radiation [30]. Mitochondrial function may
regulate cell radiosensitivity and radiation-induced cell
cycle G2 checkpoint activation, including protein chan-
ges in cyclin B1 and CDK1 [31]. Radioresistance mecha-
nisms of GSC include a decrease of apoptotic cells ratio
and cleaved caspase-9 [19]. Perhaps the reasons that
apoptotic percentage of SHG-44 and SU2 cells was sig-
nificantly different were relative to not only difference of
boron uptake but also radiation resistance and injury re-
pair of GSPC. Therefore, arrest in the G2/M phase and
induction of mitochondria-associated apoptosis are pos-
sible mechanisms of BNCT on proliferative inhibition in
SHG-44 and SU2 cells.
A previous study suggested that CD133+ GSC were
radioresistant due, in part, to enhanced DNA repair [19].
Radiation-induced delays in the G1, S and G2 phases of
the cell cycle are thought to allow periods during which
cells survey and repair DNA damage. Cells will promote
the apoptotic pathway if DNA damage cannot be re-
paired. Following exposure to high LET radiations, the
clustering of lesions in DNA induced by ionizing radi-
ation is thought to play an important role in long-term
biological effects. Thus, BNCT would offer an appre-
ciable therapeutic advantage over X-ray or γ-ray therapy.
Some clinical results demonstrated that the median
surviving times of GBM patients who received a single
BNCT treatment with BPA or BPA and BSH, or BNCT
combined with conventional radiotherapy using epither-
mal neutron sources from Finnish, Swedish, or Japanese
reactors, were equivalent or superior to those receiving
only conventional radiation therapy. These results might
be due to GSPC damage in the presence of sufficient
amounts of boron. The median surviving times of GBM
patients who received BNCT with thermal and epither-
mal from Finnish Fir-1, Swedish R2-o and Japanese
JRR-4 or KURR reactors were 11.0-21.9, 17.7 and 23.3-
27.1 months, respectively [8]. However, these results
were not satisfying enough. Boron uptake, especially in
radio- and chemo-resistant GSC, plays a key role in the
biological effects of BNCT. Some experimental methods,
including targeting molecules overexpressed on the tumor
surface, preloading compounds, increasing total dose,
extending infusion time, and changing route of adminis-
tration could increase the boron content in tumor cells,
thus improving treatment efficacy. With the improvement
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fectively damage tumor cells, without affecting peripheral
normal cells.
Conclusion
GSPC, which are resistant to current clinical radiothe-
rapy, were effectively killed by BNCT in vitro using a
prolonged neutron irradiation, but not damaged by neu-
tron radiation with BPA-free. Radiosensitivity of GSPC
was decreased compared with differentiated glioma cells
using the same dose of thermal neutron exposure and
BPA pretreatment at least due partly to low uptake of
boron. BNCT induced GSPC cell cycle arrest in the G2/M
phase and apoptosis by the mitochondria-mediated path-
way. BNCT can damage GSPC, which are resistant to
X- and γ-rays and play a key role in glioma recurrence, as
long as the cells receive enough high LET radiations from
thermal neutrons. Thus, BNCT could offer an appreciable
therapeutic advantage to prevent tumor recurrence, and
may become a promising treatment for glioma.
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